PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Andy Pasternak as Chairman of its Board of Directors, following the departure of Richard Berman, who stepped down effective January 12, 2025. This transition marks the start of a new chapter for the company as it seeks to strengthen its position in the innovative field of T cell engagers for solid tumors.
“I am honored to become the next Chairman of the Board of Directors of Context, where I expect to leverage my experience advising and building fully integrated global biopharmaceutical companies to help Context continue to deliver on the promise of T cell engagers for solid tumors,” said Pasternak. “T cell engagers is a quickly evolving field with tremendous potential, and I am excited to work with the Board and management team to keep Context at the forefront of this modality and help improve patients’ lives.”
Pasternak brings over 25 years of biopharmaceutical industry expertise to Context. Currently an Advisory Partner at Bain & Company, Pasternak has a proven track record in strategy, corporate development, and innovation leadership. His most recent role as Executive Vice President and Chief Strategy Officer at Horizon Therapeutics included spearheading the company’s corporate strategy, business development, and its $28 billion acquisition by Amgen in 2023. Before his tenure at Horizon, he was a senior partner and Head of the Healthcare Practice for the Americas at Bain & Company. Pasternak also serves as a board member at Endo, Inc. and lectures at Northwestern University’s Kellogg School of Management.
CEO Martin Lehr expressed gratitude for outgoing Chairman Richard Berman while underlining the leadership advantages Pasternak will bring to Context. “On behalf of the Board, I would like to thank Richard Berman for his support of Context as he steps down so we can welcome Andy’s extensive pharmaceutical expertise to help lead the company in this next exciting phase. We greatly appreciate Richard’s contributions over the last four years, and we wish him the best.”
Pasternak’s appointment comes as Context Therapeutics seeks to advance its leadership in the cutting-edge field of T cell engagers, which hold significant potential for transforming the treatment of solid tumors. His vision and expertise are expected to align with the company’s mission of improving patient outcomes while driving strategic growth in a rapidly evolving sector.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.